Elevated serum FSTL3 was verified in AMI patients with co-existent T2DM and NAFLD, and consistent with the results of previous studies in atherosclerosis patients and AMI animal models [21, 22]. Here, FSTL3 is linked to metabolic dysfunction-associated steatotic liver disease.